Cibc World Markets Corp Invests $364,000 in Krystal Biotech, Inc. (NASDAQ:KRYS)

Cibc World Markets Corp acquired a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 2,321 shares of the company’s stock, valued at approximately $364,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in KRYS. Commonwealth Equity Services LLC raised its stake in Krystal Biotech by 4.1% in the fourth quarter. Commonwealth Equity Services LLC now owns 4,866 shares of the company’s stock worth $762,000 after buying an additional 190 shares in the last quarter. Swiss National Bank raised its position in shares of Krystal Biotech by 8.4% in the 4th quarter. Swiss National Bank now owns 42,400 shares of the company’s stock worth $6,642,000 after acquiring an additional 3,300 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Krystal Biotech by 31.2% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,054 shares of the company’s stock worth $948,000 after purchasing an additional 1,440 shares during the last quarter. Sound View Wealth Advisors Group LLC boosted its position in Krystal Biotech by 18.3% during the fourth quarter. Sound View Wealth Advisors Group LLC now owns 1,420 shares of the company’s stock valued at $222,000 after purchasing an additional 220 shares in the last quarter. Finally, AlphaQuest LLC grew its stake in Krystal Biotech by 116.0% in the fourth quarter. AlphaQuest LLC now owns 3,020 shares of the company’s stock valued at $473,000 after purchasing an additional 1,622 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors.

Krystal Biotech Stock Performance

Shares of KRYS opened at $194.44 on Tuesday. The stock has a 50-day moving average of $167.55 and a two-hundred day moving average of $173.62. The stock has a market cap of $5.60 billion, a P/E ratio of 65.03 and a beta of 0.87. Krystal Biotech, Inc. has a one year low of $141.72 and a one year high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.29 by $0.23. The firm had revenue of $91.10 million during the quarter, compared to analysts’ expectations of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The company’s revenue for the quarter was up 116.4% compared to the same quarter last year. During the same period last year, the business posted $0.30 earnings per share. Analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on KRYS shares. Jefferies Financial Group began coverage on shares of Krystal Biotech in a report on Wednesday, March 5th. They issued a “buy” rating and a $245.00 price target on the stock. HC Wainwright restated a “buy” rating and issued a $221.00 target price on shares of Krystal Biotech in a research note on Friday, February 28th. Citigroup increased their price objective on Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a report on Thursday, February 20th. Chardan Capital raised their price objective on Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research report on Thursday, February 20th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 target price on shares of Krystal Biotech in a research report on Thursday, February 20th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $220.00.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the sale, the insider now directly owns 1,463,711 shares of the company’s stock, valued at approximately $260,233,178.69. This trade represents a 1.68 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Kathryn Romano sold 750 shares of the business’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the transaction, the chief accounting officer now directly owns 12,604 shares of the company’s stock, valued at approximately $2,208,472.88. This trade represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 14.10% of the company’s stock.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).